Symeres, a global drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), has acquired Exemplify BioPharma, a U.S.-based CRO that provides integrated drug development services in Process & Analytical Chemistry and Formulation Development to pharmaceutical and biotech partners.   Keensight Capital, a private equity manager dedicated to pan-European Growth Buyout investments and the majority shareholder in Symeres, has worked togeth...